ClinConnect ClinConnect Logo
Search / Trial NCT02497261

Predictors of Persistent Peanut Allergy at Age 5 Years

Launched by UNIVERSITY OF MANITOBA · Jul 9, 2015

Trial Information

Current as of July 21, 2025

Enrolling by invitation

Keywords

Food Allergy Peanut Sensitization Child Double Blind Placebo Controlled Challenge Prospective Cohort

ClinConnect Summary

Introduction:

Food allergy has reached epidemic levels in Canada and peanut allergy is the most prevalent and one of the more persistent food allergies among Canadian children and adults. Avoidance or later introduction of peanut has been proposed as a possible cause of the increased rates of peanut sensitization and allergy. Although delaying the introduction of peanut into children's diets is no longer recommended, many parents continue to worry about introducing peanut and some will not introduce peanut into their child's diet without a negative skin prick test to peanut. However, some ...

Gender

ALL

Eligibility criteria

  • Challenge Inclusion Criteria:
  • CHILD study participants will be eligible for challenge if they
  • 1. Have completed their 5-year-old CHILD Study visit
  • 2. Are or have been sensitized to peanut i.e. have had a positive skin prick test (wheal diameter at least 2 mm greater than the negative control) and/or allergen-specific IgE level (\>0.35 kU/L) to peanut at their 1-, 3- and/or 5-year-old CHILD study visit
  • 3. Are not eating peanut. Children who eat less than 8-10 g of peanut per month or who eat only foods that 'may contain' traces of peanut will still be eligible for inclusion.
  • Challenge Exclusion Criteria:
  • CHILD study participants will be ineligible for challenge if
  • 1. They have never had a positive skin prick test or allergen-specific IgE level to peanut
  • 2. They are eating 8-10 g of peanut at least once per month, despite having had a positive skin prick test or allergen-specific IgE level to peanut
  • 3. Their family has declined to participate
  • 4. They have a peanut skin prick test wheal size \>8mm and/or a peanut-specific IgE \>15 kU/L and a history suggestive of an IgE-mediated allergic reaction to peanut.
  • 5. They have a history of anaphylaxis to peanut or a challenge-proven diagnosis of peanut allergy within the past 1-2 years.
  • 6. They have uncontrolled asthma or any other contraindication to performing a DBPC food challenge on the day of challenge. These children may be rescheduled if their asthma control improves.
  • Blood Draw Inclusion Criteria:
  • CHILD study participants will be eligible for blood draw if they
  • 1. Have completed their 5-year-old CHILD Study visit
  • 2. Are or have been sensitized to peanut i.e. have had a positive skin prick test (wheal diameter at least 2 mm greater than the negative control) and/or allergen-specific IgE level (\>0.35 kU/L) to peanut at their 1-, 3- and/or 5-year-old CHILD study visit
  • Blood Draw Exclusion Criteria:
  • CHILD study participants will be ineligible for blood draw if
  • 1. They have never had a positive skin prick test or allergen-specific IgE level to peanut
  • 2. Their family has declined to participate
  • Immunological analyses of the blood samples are underway now that the 2 sites participating in this portion of the study (University of Manitoba and University of British Columbia) have completed their challenges. Challenges were halted in the spring.

About University Of Manitoba

The University of Manitoba, a leading research institution in Canada, is dedicated to advancing healthcare through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, the university leverages its extensive expertise in medical research, public health, and community engagement to conduct rigorous and ethical clinical studies. The institution aims to translate scientific findings into practical applications that enhance patient care and improve health outcomes. Committed to fostering a culture of excellence and integrity, the University of Manitoba prioritizes participant safety and scientific validity in all its clinical research endeavors.

Locations

Patients applied

0 patients applied

Trial Officials

Elinor Simons, MD PhD MSc

Principal Investigator

Section of Allergy, Department of Pediatrics & Child Health, University of Manitoba

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials